Abstract
MultiCellular Tumor Spheroid (MCTS) mimics the organization of a tumor and is considered as an invaluable model to study cancer cell biology and to evaluate new antiproliferative drugs. Here we report how the characteristics of MCTS in association with new technological developments can be used to explore the regionalization and the activation of cell cycle checkpoints in 3D. Cell cycle and proliferation parameters were investigated in Capan-2 spheroids by immunofluorescence staining, EdU incorporation and using cells engineered to express Fucci-red and -green reporters. We describe in details the changes in proliferation and cell cycle parameters during spheroid growth and regionalization. We report the kinetics and regionalized aspects of cell cycle arrest in response to checkpoint activation induced by EGF starvation, lovastatin treatment and etoposide-induced DNA damage. Our data present the power and the limitation of spheroids made of genetically modified cells to explore cell cycle checkpoints. This study paves the way for the investigation of molecular aspects and dynamic studies of the response to novel antiproliferative agents in 3D models.
MeSH Terms
Antimetabolites, Antineoplastic/pharmacology
Apoptosis/drug effects
Cell Culture Techniques
Cell Cycle Checkpoints/drug effects
Cytotoxins/pharmacology
Deoxycytidine/analogs & derivatives,pharmacology
Drug Screening Assays, Antitumor/methods
Humans
Models, Biological
Pancreatic Neoplasms/drug therapy,pathology
Spheroids, Cellular/drug effects,pathology
Tumor Cells, Cultured
Chemicals
Antimetabolites, Antineoplastic
Cytotoxins
Deoxycytidine
gemcitabine
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Laurent Jennifer
Université de Toulouse; ITAV-USR3505, Toulouse F-31106, France.
Frongia Céline
Cazales Martine
Mondesert Odile
Ducommun Bernard
Lobjois Valérie
References (25)
25 references, click to expand
-
Cdt1 and geminin are down-regulated upon cell cycle exit and are over-expressed in cancer-derived cell lines.
Eur J Biochem. 2004 Aug;271(16):3368-78
PMID: 15291814
-
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74
PMID: 21376230
-
Visualizing spatiotemporal dynamics of multicellular cell-cycle progression.
Cell. 2008 Feb 8;132(3):487-98
PMID: 18267078
-
Identification of a novel EGF-sensitive cell cycle checkpoint.
Exp Cell Res. 2007 Feb 1;313(3):511-26
PMID: 17157295
-
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.
Trends Mol Med. 2011 Feb;17(2):88-96
PMID: 21087899
-
Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge?
Int J Radiat Biol. 2007 Nov-Dec;83(11-12):849-71
PMID: 18058370
-
Ki67 in breast cancer: prognostic and predictive potential.
Lancet Oncol. 2010 Feb;11(2):174-83
PMID: 20152769
-
Multicellular tumor spheroids: an underestimated tool is catching up again.
J Biotechnol. 2010 Jul 1;148(1):3-15
PMID: 20097238
-
New insights into checkpoint kinase 1 in the DNA damage response signaling network.
Clin Cancer Res. 2010 Jan 15;16(2):376-83
PMID: 20068082
-
Microenvironmental regulation of proliferation in multicellular spheroids is mediated through differential expression of cyclin-dependent kinase inhibitors.
Cancer Res. 2004 Mar 1;64(5):1621-31
PMID: 14996720
-
Spheroids in radiobiology and photodynamic therapy.
Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):179-92
PMID: 11033305
-
Synchronization of the cell cycle using lovastatin.
Cell Cycle. 2008 Aug;7(15):2434-40
PMID: 18677105
-
Cell cycle, CDKs and cancer: a changing paradigm.
Nat Rev Cancer. 2009 Mar;9(3):153-66
PMID: 19238148
-
Targeting Polo-like kinase in cancer therapy.
Clin Cancer Res. 2010 Jan 15;16(2):384-9
PMID: 20068088
-
3D imaging of the response to CDC25 inhibition in multicellular spheroids.
Cancer Biol Ther. 2009 Dec;8(23):2230-36
PMID: 19823027
-
Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK1.
Cell Cycle. 2006 Nov;5(22):2555-6
PMID: 17172841
-
Is Cdc25 a druggable target?
Anticancer Agents Med Chem. 2008 Dec;8(8):837-42
PMID: 19075566
-
The CDK inhibitors in cancer research and therapy.
J Cancer Res Clin Oncol. 2011 Oct;137(10):1409-18
PMID: 21877198
-
The use of 3-D cultures for high-throughput screening: the multicellular spheroid model.
J Biomol Screen. 2004 Jun;9(4):273-85
PMID: 15191644
-
Unleashing Chk1 in cancer therapy.
Cell Cycle. 2011 Jul 1;10(13):2121-8
PMID: 21610326
-
Cell and environment interactions in tumor microregions: the multicell spheroid model.
Science. 1988 Apr 8;240(4849):177-84
PMID: 2451290
-
Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer.
BMC Cancer. 2012 Jan 13;12:15
PMID: 22244109
-
Multicellular resistance: a paradigm for clinical resistance?
Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):193-207
PMID: 11033306
-
Aurora kinases and their inhibitors: more than one target and one drug.
Adv Exp Med Biol. 2008;610:54-73
PMID: 18593015
-
Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway.
Biochem Pharmacol. 2011 Dec 1;82(11):1663-72
PMID: 21907187